This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C69 | Special Copayment Reduction: V193 | copayment 5% (for 5 years from the date of cancer patient registration) C69.0 conjunctiva, C69.1 cornea, C69.2 retina, C69.3 choroid, C69.4 ciliary body, C69.5 lacrimal gland and duct, C69.6 orbit, C69.8 overlapping, C69.9 unspecified |
| B. Synonyms | Uveal melanoma, choroidal melanoma, retinoblastoma, conjunctival cancer, orbital cancer, lacrimal gland cancer, ocular adnexal lymphoma, Uveal melanoma, Retinoblastoma, Conjunctival carcinoma, Lacrimal gland carcinoma |
| C. Adult onset | Varies by disease — uveal melanoma (very high, mainly in the 50s–60s); retinoblastoma (specific to children, mean age at diagnosis 13 months); conjunctival and lacrimal gland cancer (adult onset) |
Descriptions of malignant tumors of the eye and adnexa date back to antiquity, but modern medical understanding began with the development of histopathology in the 19th century. Retinoblastoma was first described by Pieter Pawius in 1597, and in 1864 Virchow published a systematic study of its cellular origin. With the publication of Knudson's two-hit hypothesis in the 1970s (the theory that bilateral tumors require two mutations, presupposing a germline mutation), retinoblastoma became a pioneering model for tumor suppressor gene research, and the RB1 gene was identified in 1986.
Uveal melanoma began to attract clinical attention in the late 19th century with the development of ophthalmic surgery. In 1929, enucleation was first established as the standard treatment, and with the subsequent introduction of radiation therapy (brachytherapy, proton therapy) in the 1970s–80s, the era of eye-preserving treatment began. The COMS (Collaborative Ocular Melanoma Study) (1986–2006) demonstrated that survival with brachytherapy and enucleation is equivalent in medium-sized uveal melanoma. For conjunctival cancer, Bowman first described squamous cell carcinoma in 1854, and ultraviolet light and HPV were recognized as etiological factors only in the late 20th century. Malignant tumors of the lacrimal gland are rare, so systematic research is limited, but since the 1990s orbital evaluation using CT/MRI has become the diagnostic standard.
The causes of malignant tumors of the eye and adnexa differ by tumor type. The primary risk factor for uveal melanoma is ultraviolet (UV) exposure. Risk increases with light-colored irises (blue, green), fair skin, and light eye color, which explains why incidence is markedly higher in White people than in Asians. A BAP1 tumor predisposition syndrome (BAP1-TPDS) has been reported in which carriers of a germline BAP1 mutation have a markedly increased risk of uveal melanoma, mesothelioma, and cutaneous melanoma.
In retinoblastoma, 40% of cases are hereditary (RB1 germline mutation) and 60% are nonhereditary sporadic mutations. The hereditary form is characteristically bilateral and multifocal, while the nonhereditary form is mostly unilateral. For conjunctival cancer (conjunctival squamous cell carcinoma), UV-B exposure, HPV type 16/18 infection, and immunosuppressed states (HIV, post-transplant) are risk factors. Malignant tumors of the lacrimal gland are associated with a history of prior head and neck radiation therapy. Orbital lymphoma is related to immune impairment and chronic B-cell activation (autoimmune diseases such as Sjögren syndrome).
The most characteristic molecular abnormalities of uveal melanoma are GNAQ and GNA11 gene mutations, found in 83–95% of all uveal melanomas. These mutations keep the guanine nucleotide-binding protein (Gα protein) constantly active, continuously activating the MAP kinase pathway. Compared with GNAQ mutations, GNA11 mutations are more strongly associated with BAP1 loss, monosomy 3, and gain of the long arm of chromosome 8 (8q gain), and carry a poor prognosis. Somatic mutations of BAP1 (BRCA1-associated protein 1) are closely associated with metastatic progression, and germline variants cause BAP1 tumor predisposition syndrome.
In retinoblastoma, biallelic loss of the RB1 gene (13q14) is the essential carcinogenic event. The RB1 protein is a cell cycle regulator (inhibiting the E2F transcription factor), and loss of its function induces unlimited proliferation of retinal progenitor cells. Patients with bilateral retinoblastoma have a markedly high risk of second malignancies (especially osteosarcoma and radiation-induced sarcoma). In conjunctival squamous cell carcinoma, TP53 mutations and CDKN2A deletions are frequent, and in HPV-related tumors, inactivation of p53 and Rb by the E6/E7 proteins is the main mechanism. From a pharmacogenomic perspective, because uveal melanoma progresses through the GNAQ/GNA11→PKC/MEK→ERK pathway, MEK inhibitors (selumetinib, binimetinib) and PKC inhibitors (IDE196) are under clinical study.
Uveal melanoma is the most common primary intraocular malignancy in adults, with about 2,000 new diagnoses annually in the United States (4–6 per 100,000 population). Incidence is high in Western White populations and markedly rare in Asians. There are no precise statistics for incidence in Korea, but it is estimated to be less than 1/5 of the incidence in White people. It occurs mainly in the 50s–60s, and iris melanoma has a younger age of onset and a better prognosis than choroidal and ciliary body melanoma.
Retinoblastoma is the representative childhood eye cancer, occurring in about 1 in 18,000–30,000 people worldwide. The mean age at diagnosis is 13 months, and more than 95% are diagnosed before age 5. In Korea, too, it accounts for most childhood eye cancers. Conjunctival squamous cell carcinoma has a high incidence in countries near the equator with high UV exposure and is also increasing in areas of HIV prevalence. Orbital lymphoma is a type of ocular adnexal lymphoma, of which MALT lymphoma is the most common, and occurs mainly in adults. Malignant tumors of the lacrimal gland account for about 5% of all ocular adnexal tumors.
The pathogenesis of uveal melanoma begins in the melanocytes of the uvea. Hyperactivation of Gα11/Gαq by GNAQ/GNA11 mutations continuously stimulates downstream signaling pathways (PLCβ→PKC→ERK, PI3K-Akt, YAP, etc.), promoting cell proliferation, survival, and migration. It initially exists as a benign choroidal nevus, and malignant transformation occurs as additional genetic abnormalities (BAP1 loss, monosomy 3, 8q gain, etc.) accumulate. Metastasis occurs mainly hematogenously, and the liver is overwhelmingly the most common site of metastasis.
In retinoblastoma, loss of the RB1 protein releases inhibition of the E2F transcription factor, allowing unrestricted entry into S phase. Subsequently, additional abnormalities such as MYCN amplification, MDM4 amplification, and CDK4/6 activation accelerate malignant transformation. In conjunctival squamous cell carcinoma, TP53 mutations in the form of UV-induced C→T or CC→TT transitions cause clonal expansion, progressing from dysplasia → carcinoma in situ → invasive squamous cell carcinoma. In HPV-positive tumors, suppression of p53 and Rb function by E6/E7 accelerates this dysplasia continuum.
Symptoms of malignant tumors of the eye and adnexa vary with tumor location and size. Uveal melanoma (choroidal/ciliary body) is often asymptomatic early on, and a high proportion are found incidentally during eye examinations. As the tumor grows, vitreous floaters, visual field defects, photopsia, and decreased visual acuity appear. When choroidal detachment or retinal detachment accompanies it, sudden vision loss occurs. Iris melanoma is seen as a pigmented mass on the iris and may cause pupil distortion and elevated intraocular pressure.
The most common initial symptom of retinoblastoma is leukocoria (white pupillary reflex), in which the pupil appears white without the red-eye effect in photographs. Strabismus is the second most common symptom. Conjunctival cancer appears as a pink or gray fleshy lesion on the conjunctiva, accompanied by ocular redness, foreign body sensation, and tearing. Lacrimal gland tumors present as painful or painless swelling of the outer upper eyelid, which may be accompanied by proptosis. Orbital tumors cause proptosis, diplopia, and impaired eye movement.
On eye examination, direct and indirect ophthalmoscopy can identify a pigmented mass of the choroid or retina and exudative retinal detachment. Slit-lamp examination shows an iris mass and tumor cells or blood in the anterior chamber. On ultrasound (B-scan), uveal melanoma appears as a characteristic mushroom-shaped mass with low internal reflectivity. Fluorescein angiography (FFA) shows the double circulation pattern of choroidal tumors, and indocyanine green angiography (ICGA) is also used to assess lesion characteristics.
On ocular ultrasound, choroidal melanoma is typically mushroom- or dome-shaped, with low internal echoes and a vascular pattern. In retinoblastoma, characteristic calcification is seen on ultrasound and CT. Besides leukocoria, neovascular glaucoma and tumor invasion of the anterior chamber may appear as signs. Proptosis is a characteristic sign of orbital and lacrimal gland tumors and is measured with a Hertel exophthalmometer. On systemic metastatic evaluation, hepatomegaly may be found with liver metastasis, and rarely subcutaneous nodules may be palpable.
There is no standardized eye tumor screening program for the general population, but the following approaches are recommended for children and high-risk groups. For retinoblastoma, when there is an affected family member or a confirmed RB1 germline mutation carrier, regular fundus examination under general anesthesia (EUA: examination under anesthesia) is performed from immediately after birth. Under the International Intraocular Retinoblastoma Classification (IIRC), early detection and treatment are critically important for survival and eye preservation.
In high-risk groups for uveal melanoma (carriers of hereditary BAP1 mutations, people with multiple choroidal nevi), regular dilated fundus examination and ophthalmic ultrasound are performed every 1–2 years. When conjunctival intraepithelial neoplasia (CIN) is identified in conjunctival lesions, regular follow-up examinations are needed. In Korea, checking for leukocoria during routine pediatric eye examinations is important for early detection of retinoblastoma, and parental education to recognize leukocoria in photographs is used as an effective early detection method. Smartphone app-based leukocoria detection tools are also being used at the research stage.
The key to diagnosing malignant tumors of the eye and adnexa is the integration of clinical examination, ophthalmic imaging, and tissue biopsy. Uveal melanoma is mostly diagnosed clinically, and ophthalmic ultrasound (B-scan), fundus photography, fluorescein angiography (FFA/ICGA), and orbital MRI are the standard means of evaluation. Biopsy is usually avoided because of the risk of seeding, but fine needle aspiration biopsy (FNAB) is performed when the diagnosis is uncertain. For retinoblastoma, clinical diagnosis (fundus examination, ultrasound, MRI) takes priority, and biopsy is absolutely contraindicated. Calcification on CT and a retinal mass on MRI are characteristic.
For systemic staging, liver ultrasound or MRI (uveal melanoma) and brain and spine MRI and bone marrow examination (high-risk retinoblastoma) are performed. Conjunctival lesions are diagnosed by excisional biopsy or impression cytology. Orbital tumors require CT-guided biopsy or open biopsy after CT and MRI. Molecular genetic testing of uveal melanoma (GNAQ/GNA11/BAP1/monosomy 3/8q gain) is used for prognostic classification and stratification of metastatic risk. For lacrimal gland tumors, PET-CT is useful for staging.
Treatment of uveal melanoma is individualized according to size, location, and vision. For small tumors (<10mm diameter, <2.5mm height), observation or local treatment (thermotherapy, photodynamic therapy) is considered. For medium-sized tumors (2.5–10mm height), episcleral plaque brachytherapy—mainly I-125 or Ru-106—is the standard treatment because it preserves the eye with survival equivalent to enucleation. Proton beam radiotherapy protects surrounding tissue with excellent dose distribution, particularly for thick tumors (>8mm) or tumors close to the optic nerve or macula. Enucleation is chosen for large tumors, eyes with vision loss, or uncontrollable elevated intraocular pressure.
For metastatic uveal melanoma, conventional chemotherapy has limited efficacy, and MEK inhibitors (selumetinib, binimetinib) and PKC inhibitors (IDE196/darovasertib) are under clinical study. For retinoblastoma, the current standard is to shrink the tumor with systemic chemotherapy (vincristine+etoposide+carboplatin, VEC) and then apply local treatment (thermotherapy, cryotherapy, laser), and intra-arterial chemotherapy is also used. Unilateral advanced retinoblastoma in which the eye cannot be preserved requires enucleation. Conjunctival cancer is treated with wide excision followed by radiation therapy or topical chemotherapy (mitomycin-C, 5-FU).
The prognosis of uveal melanoma varies with tumor size, location, and molecular characteristics. The 5-year overall survival rate for small tumors is about 85–90%, but less than 50% for large tumors. Once metastasis occurs, median survival is only about 6–12 months, and since there is still no effective treatment for metastatic uveal melanoma, the prognosis is very poor. Monosomy 3 and BAP1 loss are strong poor prognostic factors for the development of metastasis. The 5-year metastasis rate after local treatment is about 25–50%.
Retinoblastoma has excellent treatment outcomes in developed countries, with a 5-year survival rate of over 95%. However, in low-income countries, survival is low due to delayed diagnosis, and the eye preservation rate is also low. Patients with hereditary retinoblastoma have a high risk of second malignancies (osteosarcoma, radiation-related sarcoma, melanoma, etc.) and need long-term follow-up. Conjunctival squamous cell carcinoma has a favorable prognosis when detected and treated early, but with orbital invasion the recurrence rate is high and the prognosis is poor. For lacrimal gland carcinoma, the 5-year survival rate varies by type, and adenoid cystic carcinoma recurs frequently and has a poor long-term prognosis.
UV protection is the most important factor in preventing uveal melanoma and conjunctival cancer. Wearing UV-blocking sunglasses (blocking UV-A/B up to 400nm) is recommended, especially for people with fair skin and light eye color. Eye protection is needed in environments with high UV intensity (near the equator, at high altitude, in snow). HPV vaccination may contribute to preventing the HPV-related subtype of conjunctival squamous cell carcinoma and is especially important in immunosuppressed patients. In people with HIV infection, maintaining immune function with antiretroviral therapy helps prevent conjunctival cancer.
Management of hereditary risk groups is important. Newborns in families of RB1 germline mutation carriers should receive regular EUA at a specialized ophthalmology center from immediately after birth. Carriers of germline BAP1 mutations need regular dermatologic (melanocytic tumors), chest (mesothelioma), and abdominal (kidney cancer) monitoring in addition to regular eye examinations. In Korea, eye examinations are included in infant and child health checkups, contributing to early detection of retinoblastoma. Preventive genetic counseling through molecular genetic family testing is recommended for high-risk families.